Randomized, double-blind, split-side, comparison study of moisturizer containing
licochalcone A and 1% hydrocortisone in the treatment of childhood atopic
dermatitis.
Author(s): Wananukul S(1), Chatproedprai S, Chunharas A, Limpongsanuruk W, Singalavanija S,
Nitiyarom R, Wisuthsarewong W.
Affiliation(s): Author information:
(1)Division of Pediatric Dermatology, Department of Pediatrics, Faculty of Medicine,
Chulalongkorn University, Bangkok, Thailand. siriwanwananukul@yahoo.com
Publication date & source: 2013, J Med Assoc Thai. , 96(9):1135-42
BACKGROUND: Atopic dermatitis (AD) is a common chronic inflammatory skin lesion
in children. Topical corticosteroid is the mainstay of treatment.
OBJECTIVE: To compare the efficacy of moisturizer containing licochalcone A
(LicA) and 1% hydrocortisone for the treatment of mild to moderate childhood AD.
MATERIAL AND METHOD: This was a multicenter randomized, prospective, split-side,
double-blind study in 55 children between the age of three months and 14 years.
Patients with AD were treated twice daily, simultaneously with either Lic A or 1%
hydrocortisone on opposite sides of the lesion. The SCORAD and transepidermal
water loss (TEWL) were performed at the baseline, 2-week, and 4-week visits. Lic
A was used on both sides of the body for another four weeks to see the effects
and TEWL.
RESULTS: In a randomized period, both products were equally effective in the
treatment. SCORAD decreased significantly from baseline for both treatments
throughout the first four weeks (p < 0.001). There was no statistically
significant difference in SCORAD between both treatments (p = 0.321 and p = 0.146
at week 2 and 4, respectively). Lic A had statistically significant decrease in
TEWL (p = 0.027 and p = 0.03 at weeks 2 and 4, respectively). One patient had
infection on skin lesions of both sides of the body. Forty-three patients
continued to the period of using Lic A on both sides of the body. SCORAD and TEWL
were comparable to the end of the randomized period and significantly lower from
baseline (p < 0.001). Skin lesions flared up in three patients (7.5%).
CONCLUSION: Lic A had a similar result in terms of SCORAD compared to 1%
hydrocortisone for the treatment of mild and moderate AD. TEWL was significantly
lower than baseline on the side that used Lic A. Continuing use of Lic A for four
weeks can maintain clinical and barrier improvement.
|